Castle Biosciences (CSTL) Non-Current Assets (2018 - 2026)

Castle Biosciences has reported Non-Current Assets for 9 years, with the latest figure at $220.1 million in Q2 2026.

• Quarterly Non-Current Assets rose 12.25% year-over-year to $220.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $861.7 million (up 25.01% YoY) and the FY2025 annual result came in at $217.5 million, up 27.11% from the prior year.
• Non-Current Assets climbed to $220.1 million in Q2 2026 per CSTL's latest filing, from $218.9 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $220.1 million in Q2 2026 and troughed at $108.0 million in Q1 2022.
• A 5-year average of $171.2 million and a median of $160.6 million in 2022 frame the typical range for Non-Current Assets.
• The sharpest annual moves came in 2022 and 2025: Non-Current Assets soared 912.79% in 2022, then retreated 6.39% in 2025.
• Over 5 years, Non-Current Assets stood at $155.0 million in 2022, then increased by 1.72% to $157.7 million in 2023, then climbed by 8.48% to $171.1 million in 2024, then climbed by 27.11% to $217.5 million in 2025, then advanced by 1.2% to $220.1 million in 2026.
• According to Business Quant data, Non-Current Assets over the past three periods registered $220.1 million, $218.9 million, and $217.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.